drugset
drugset / Trial / NCT03860038

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT03860038 ↗

Phase 2 Completed 113 enrolled TJ Biopharma Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines of treatment.

Timeline

Start
2019-01-28
Primary completion
2023-01-28
Completion
2023-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Felzartamab Monoclonal antibody 16 mg/kg —
Background Dexamethasone Small molecule 40 mg —

Indications

plasma cell myeloma